Further studies identified fatty acid translocase (FAT/CD36) as a key fatty acid transport protein in prostate cancer while inhibition of FAT/CD36 with a monoclonal antibody attenuated tumor growth in a prostate patient-derived xenograft (PDX) and PDX-derived organoids. This evidence concerns the gene CD36 and prostatitis.